
浏览全部资源
扫码关注微信
1.河南护理职业学院, 河南 安阳 455005
2.山西医科大学 第二附属医院, 太原 030001
3.安阳市人民医院, 河南 安阳 455002
王艾青,副教授,从事临床与教学工作,E-mail:3131920003@qq.com
牛增志,硕士,主任医师,从事中医临床工作,E-mail:362456311@qq.com
网络出版日期:2019-12-18,
纸质出版日期:2020-06-20
移动端阅览
王艾青,郭锦丽,牛增志等.养心汤加减辨治对肺心病缓解期心肺气虚证疾病的进展[J].中国实验方剂学杂志,2020,26(12):139-144.
WAMG Ai-qing,GUO Jin-li,NIU Zeng-zhi,et al.Effect of Modified Yangxintang on Chronic Pulmonary Heart Disease with Syndrome of Deficiency of Heart and Lung Qi[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(12):139-144.
王艾青,郭锦丽,牛增志等.养心汤加减辨治对肺心病缓解期心肺气虚证疾病的进展[J].中国实验方剂学杂志,2020,26(12):139-144. DOI: 10.13422/j.cnki.syfjx.20200431.
WAMG Ai-qing,GUO Jin-li,NIU Zeng-zhi,et al.Effect of Modified Yangxintang on Chronic Pulmonary Heart Disease with Syndrome of Deficiency of Heart and Lung Qi[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(12):139-144. DOI: 10.13422/j.cnki.syfjx.20200431.
目的
2
探讨养心汤加减辨治对缓解期肺心病(CPHD)心肺气虚证患者的控制效果及对免疫功能和炎症因子的影响。
方法
2
128例患者按随机数字表法分为对照组和观察组各64例。对照组采用西医综合康复治疗,气流受限采用沙美特罗替卡松粉吸入剂,每次1吸,1~2次/d;咳嗽痰多口服盐酸氨溴索片,1~2片/次,3次/d,连用1~2周。观察组在对照组治疗的基础上,给予养心汤加减辨治内服,1剂/d,5 d/周。记录48周的观察期间的急性加重次数、感冒次数;记录治疗前后肺动脉收缩压(PASP),肺动脉平均压(MPAP),左室射血分数(LVEF),每搏输出量(SV)和心输出量(CO);进行治疗前后改良版英国医学硏究委员会呼吸问卷(mMRC问卷)评分、明尼苏达心力衰竭生活质量量表(MLHFQ)评分、心肺气虚证评分和6 min步行试验(6 MWT);检测治疗前后
N
末端B型利钠肽原(NT-proBNP),肿瘤坏死因子-
α
(TNF-
α
),白细胞介素-6(IL-6),一氧化氮(NO)和内皮素-1(ET-1)和T淋巴细胞亚群(CD3
+
,CD4
+
,CD8
+
,CD4
+
/CD8
+
)水平。
结果
2
观察组临床疗效优于对照组(
Z
=2.108,
P<
0.05);在48周期间观察期间,观察组急性加重次数、感冒次数均少于对照组(
P
<
0.01);观察组患者PASP,MPAP水平均低于对照组(
P
<
0.01);观察组NT-proBNP水平低于对照组(
P
<
0.01),LVEF,SV,CO均高于对照组(
P
<
0.01);观察组患者mMRC问卷,MLHFQ,心肺气虚证评分均低于对照组(
P
<
0.01),治疗后观察组6 MWT多于对照组(
P
<
0.01);观察组CD3
+
,CD4
+
水平和CD4
+
/CD8
+
均高于对照组(
P
<
0.05),CD8
+
水平低于对照组(
P
<
0.05);治疗后观察组TNF-
α
,IL-6,ET-1均低于对照组(
P
<
0.01),NO高于对照组(
P
<
0.01)。
结论
2
在抗炎、平喘、止咳等综合康复治疗的基础上,采用养心汤加减辨证内服治疗缓解期CPHD心肺气虚证患者,可提高免疫功能,可减轻心、肺症状,提高心肺功能和生活质量,还能抑制炎症反应,改善血管内皮功能,降低肺动脉高压,改善了病情的进展,临床疗效优于单纯西医康复治疗。
Objective
2
To discuss the effect of modified Yangxintang on chronic pulmonary heart disease (CPHD) with syndrome of deficiency of heart and lung Qi and progress of disease.
Method
2
One hundred and twenty-eight patients were randomly divided into control group 64 cases and observation group 64 cases by random number table. Patients in control group got comprehensive rehabilitation measures of western medicine. Those who had respiratory distress got Salmeterol ticasone powder inhaler
1-2 times/day
1 inhale/time.And those who had cough and phlegm got Ambroxol hydrochloride tablets for 1-2 week
1-2 tablet/time
3 times/day. In addition to the therapy of control group
patients in observation group was also added with modified Yangxintang
1 dose/day
5 days/week. Record the and times of acute aggravate and cold
pulmonary artery systolic pressure (PASP)
mean pulmonary artery pressure (MPAP)
left ventricular ejection fraction (LVEF)
stroke volume (SV) and cardiac output (CO) were recorded during 48 weeks. Before and after treatment
scores of modified British medical research council respiratory questionnaire (mMRC questionnaire)
Minnesota Heart Failure Quality of life scale (MLHFQ)
syndrome of deficiency of heart and lung Qi and 6-minute walking test (6 MWT) were scored. And levels of
N
-terminal B-type natriuretic peptide (NT-proBNP)
tumor necrosis factor-
α
(TNF-
α
)
interleukin-6 (IL-6)
nitric oxide (NO)
endothelin (ET-1)
CD3
+
CD4
+
CD8
+
and CD4
+
/CD8
+
were detected.
Result
2
The clinical efficacy in observation group was better than that in control group (
Z
=2.108
P<
0.05). During 48 weeks of observation period
times of acute aggravate and cold in observation group were less than those in control group (
P<
0.01). Levels of PASP
MPAP and NT-proBNP were lower than those in control group (
P<
0.01). And levels of LVEF
SV
CO
6 MWT and NO were higher than those in control group (
P<
0.01)
levels of CD3
+
CD4
+
and CD4
+
/CD8
+
were higher than those in control group (
P<
0.05). And levels of mMRC
MLHFQ
score of syndrome of deficiency of heart and lung Qi
TNF-
α
IL-6
ET-1
CD8
+
and were all lower than those in control group (
P<
0.01
P<
0.05).
Conclusion
2
In addition to anti-inflammatory
anti-asthmatic and anti-tussive therapies
modified Yangxintang can improve the immune function
relieve the symptoms of heart and lung
improve the function of heart and lung and the quality of life
inhibit the inflammatory reaction
improve the function of vascular endothelium
reduce the pulmonary hypertension
control the progress of disease.
中华医学会 , 中华医学会杂志社 , 中华医学会全科医学分会 , 等 . 慢性肺源性心脏病基层诊疗指南(2018年) [J]. 中华全科医师杂志 , 2018 , 17 ( 12 ): 959 - 965 .
中华中医药学会肺系病专业委员会 . 慢性肺原性心脏病中医诊疗指南(2014版) [J]. 中医杂志 , 2014 , 55 ( 6 ): 526 - 531 .
宋彦伟 , 杨如意 . 中医药治疗慢性肺心病的研究进展 [J]. 中西医结合心血管病电子杂志 , 2017 , 5 ( 16 ): 177 - 178 .
陈波 , 孙天强 . 中药养心汤药理及临床应用研究进展 [J]. 亚太传统医药 , 2018 , 14 ( 3 ): 85 - 88 .
李晶洁 , 于彦伟 , 王召军 , 等 . 养心汤治疗舒张性心力衰竭的临床研究 [J]. 中医药信息 , 2012 , 29 ( 1 ): 63 - 65 .
陶静怡 . 养心汤辅助治疗慢性肺心病急性发作120例 [J]. 山东中医药大学学报 , 2013 , 37 ( 1 ): 37 - 38 .
陈果 , 李小惠 , 李蔚 . 应用改良版英国医学研究委员会呼吸问卷、自我评估测试问卷和临床问卷评估慢性阻塞性肺疾病患者健康状况的比较研究 [J]. 实用医院临床杂志 , 2015 , 12 ( 1 ): 59 - 60 .
王贤良 , 刘洪伟 , 毛静远 , 等 . 基于中国文化改良明尼苏达心力衰竭生存质量量表的测评 [J]. 中国中西医结合杂志 , 2016 , 36 ( 9 ): 1072 - 1075 .
张勇 , 邱军杰 , 安亚东 , 等 . 氯沙坦联合环磷腺苷葡胺对肺心病患者心肺及免疫功能的影响 [J]. 现代生物医学进展 , 2018 , 18 ( 5 ): 931 - 934 .
MICHAEL R , PINSK Y . The right ventricle: interaction with the pulmonary circulation [J]. Crit Care , 2016 , 20 ( 1 ): 266 - 272 .
卢绪香 , 杨传华 . 慢性肺源性心脏病与肺肾心的关系探析 [J]. 江苏中医药 , 2016 , 48 ( 2 ): 6 - 8 .
阮欢荣 , 马锦地 , 李建生 , 等 . 慢性肺源性心脏病中医病因病机分析 [J]. 中医学报 , 2018 , 33 ( 1 ): 37 - 41 .
中华医学会心血管病分会 . 中国心力衰竭诊断和治疗指南2014 [J]. 中华心血管病杂志 , 2014 , 42 ( 2 ): 98 - 122 .
JIANG P , MA D , WANG X , et al . Astragaloside IV prevents obesity-associated hypertension by improving pro-Inflammatory reaction and leptin resistance [J]. Mol Cells , 2018 , 41 ( 3 ): 244 - 255 .
NOORI N M , SHAHRAMIAN , TEIMOURI A , et al . Serum levels of tumor necrosis factor- α and interleukins in children with congenital heart disease [J]. J Tehran Heart Cent , 2017 , 12 ( 1 ): 15 - 22 .
STUPNYTSKA A , STUPNYTSKA G . Effect of statins on endothelial dysfunction in patients with chronic obstructive pulmonary disease and metabolic syndrome [J]. Respiration , 2014 , 71 ( 1 ): 45 - 50 .
SALEBY J , BOUZINA H , LUNDGREN J , et al . Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension [J]. Scand Cardiovasc J , 2017 , 51 ( 5 ): 1 - 10 .
ROBERTS W C , SHAFII A E , GRAYBURN P A , et al . Clinical and morphologic features of acute, subacute and chronic cor pulmonale (pulmonary heart disease) [J]. Am J Cardiol , 2015 , 115 ( 5 ): 697 - 703 .
0
浏览量
16
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621